Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer

Masaki Kashihara, Koichi Azuma, Akihiko Kawahara, Yuji Basaki, Satoshi Hattori, Takashi Yanagawa, Yasuhiro Terazaki, Shinzo Takamori, Kazuo Shirouzu, Hisamichi Aizawa, Kenji Nakano, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono

    Research output: Contribution to journalArticlepeer-review

    41 Citations (Scopus)

    Abstract

    INTRODUCTION: Nuclear expression of Y-box binding protein-1 (YB-1) is closely associated not only with global drug resistance and expression of several growth factor receptors in various human malignancies but also with overall patient survival. METHODS: The effect of YB-1 knockdown on expression of epidermal growth factor receptor (EGFR) family proteins was examined by Western blot using human lung cancer cell lines. Immunohistochemistry was used to evaluate the expression of nuclear YB-1 and EGFR family proteins in patients with non-small cell lung cancer (NSCLC) (n = 104). RESULTS: In the five NSCLC cell lines, expressions of EGFR, human epidermal growth factor receptor 2 (HER2), HER3, and hepatocyte growth factor receptor (c-Met) in PC-9 cells; of HER2 and c-Met in EBC-1 cells; and of HER3 in QG56 cells were down-regulated by YB-1 knockdown. By immunohistochemical analysis, we observed that HER3 expression was significantly negatively correlated with nuclear YB-1 expression in squamous cell carcinoma (p = 0.038). HER2 expression was positively correlated with nuclear YB-1 expression in adenocarcinoma (p = 0.052). Nuclear expression of YB-1 correlated with overall survival of all patients (p = 0.028) and of patients with adenocarcinoma (p = 0.007). Furthermore, there was a significant difference in therapeutic efficacies of gefitinib between patients with nuclear YB-1 expression and those with non-nuclear YB-1 expression in patients with NSCLC (p = 0.004, n = 26) but not between those with high and those with low expression of EGFR, HER2, HER3, and c-Met. CONCLUSION: Nuclear YB-1 expression might be essential for the malignant phenotype in lung cancer patients and might be an important biomarker for the development of therapeutic strategy against NSCLC.

    Original languageEnglish
    Pages (from-to)1066-1074
    Number of pages9
    JournalJournal of Thoracic Oncology
    Volume4
    Issue number9
    DOIs
    Publication statusPublished - Sep 2009

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Pulmonary and Respiratory Medicine

    Fingerprint Dive into the research topics of 'Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer'. Together they form a unique fingerprint.

    Cite this